A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)

Molecular Genetics and Metabolism

Volumn 90, Issue 3 SPEC. ISS., 2007, Pages 329-337

  Muenzer, Joseph ^a   Gucsavas Calikoglu, Muge ^a   McCandless, Shawn E ^a,c   Schuetz, Thomas J ^b   Kimura, Alan ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SHIRE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Enzyme replacement therapy; Glycosaminoglycans; Hunter syndrome; Iduronate 2 sulfatase; Idursulfase; Lysosomal storage disorder; MPS II; Mucopolysaccharidosis II

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; IMMUNOGLOBULIN ANTIBODY; PLACEBO; RECOMBINANT ENZYME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIBODY PRODUCTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENZYME REPLACEMENT; GLYCOSAMINOGLYCAN METABOLISM; HUMAN; HUNTER SYNDROME; LIVER WEIGHT; MALE; OPEN STUDY; OXYGEN SATURATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SEIZURE; SIDE EFFECT; SPLEEN WEIGHT; UNCONSCIOUSNESS; URINALYSIS; URINARY EXCRETION; WALKING;

EID: 33846899175     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.09.001     Document Type: Article

References (40)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R. (Ed). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York 3421-3452
2. McKusick V.A. Relative frequency of the Hurler and Hunter syndromes. N. Engl. J. Med. 283 (1970) 1466-1468
3. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. JAMA 281 (1999) 249-254
4. Young I.D., and Harper P.S. Incidence of Hunter's syndrome. Hum. Genet. 60 (1982) 391-392
5. The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. (accessed 24.08.06).
6. Lissens W., Seneca S., and Liebaers I. Molecular analysis in 23 Hunter disease families. J. Inherit. Metab. Dis. 20 (1997) 453-456
7. Kim C.H., Hwang H.Z., Song S.M., Paik K.H., Kwon E.K., Moon K.B., Yoon J.H., Han C.K., and Jin D.K. Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations. Hum. Mutat. 21 (2003) 449-450
8. Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K., Muzny D.M., Dugan-Rocha S.P., Nelson D.L., Pettersson U., and Gibbs R.A. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum. Mol. Genet. 6 (1997) 479-486
9. Vafiadaki E., Cooper A., Heptinstall L.E., Hatton C.E., Thornley M., and Wraith J.E. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch. Dis. Child 79 (1998) 237-241
10. Li P., Bellows A.B., and Thompson J.N. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J. Med. Genet. 36 (1999) 21-27
11. Vellodi A., Young E., Cooper A., Lidchi V., Winchester B., and Wraith J.E. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22 (1999) 638-648
12. Kaye E.M. Lysosomal storage diseases. Curr. Treat. Options Neurol. 3 (2001) 249-256
13. McKinnis E.J., Sulzbacher S., Rutledge J.C., Sanders J., and Scott C.R. Bone marrow transplantation in Hunter syndrome. J. Pediatr. 129 (1996) 145-148
14. Bergstrom S.K., Quinn J.J., Greenstein R., and Ascensao J. Long-term follow-up of a patient transplanted for Hunter's disease type IIB: a case report and literature review. Bone Marrow Transplant. 14 (1994) 653-658
15. Coppa G.V., Gabrielli O., Zampini L., Pierani P., Giorgi P.L., Jezequel A.M., Orlandi F., Miniero R., Busca A., De Luca T., et al. Bone marrow transplantation in Hunter syndrome (mucopolysaccharidosis type II): two-year follow-up of the first Italian patient and review of the literature. Pediatr. Med. Chir. 17 (1995) 227-235
16. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E., et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
17. Schiffmann R., Kopp J.B., Austin III H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., and Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285 (2001) 2743-2749
18. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., and Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 345 (2001) 9-16
19. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 144 (2004) 581-588
20. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
21. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., Yu Z.F., Swiedler S.J., and Hopwood J.J. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115 (2005) e681-e689
22. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., and Swiedler S.J. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or RHASB) and follow-on, open-label extension study. J. Pediatr. 148 (2006) 533-539
23. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., and Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr. Suppl. 91 (2002) 98-99
24. Muenzer J., Wraith E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Calikoglu M., Vijayaraghavan S., Wendt S., Puga A., Ulbrich B., Shinawi M., Cleary M., Conway A.M., and Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis type II (Hunter syndrome). Genet. Med. 8 (2006) 465-473
25. de Jong J.G., Wevers R.A., Laarakkers C., and Poorthuis B.J. Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin. Chem. 35 (1989) 1472-1477
26. de Jong J.G., Wevers R.A., and Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of prote: An improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin. Chem. 38 (1992) 803-807
27. Farraher S.W., Jara H., Chang K.J., Hou A., and Soto J.A. Liver and spleen volumetry with quantitative MR imaging and dual-space clustering segmentation. Radiology 237 (2005) 322-328
28. Schlesinger A.E., Edgar K.A., and Boxer L.A. Volume of the spleen in children as measured on CT scans: normal standards as a function of body weight. AJR Am. J. Roentgenol. 160 (1993) 1107-1109
29. Devereux R.B. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9 (1987) II19-II26
30. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 166 (2002) 111-117.
31. American Thoracic Society, Standardization of Spirometry, 1994 Update. Am. J. Respir. Crit. Care Med. 152 (1995) 1107-1136.
32. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur. Respir. J. Suppl. 16 (1993) 5-40
33. Norkin C.C., and White D.J. Measurement of Joint Motion. A Guide to Goniometry. third ed. (2003), FA Davis Co., Philadelphia, PA
34. Kushida C.A., Littner M.R., Morgenthaler T., Alessi C.A., Bailey D., Coleman Jr. J., Friedman L., Hirshkowitz M., Kapen S., Kramer M., Lee-Chiong T., Loube D.L., Owens J., Pancer J.P., and Wise M. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 28 (2005) 499-521
35. Caples S.M., Gami A.S., and Somers V.K. Obstructive sleep apnea. Ann. Intern. Med. 142 (2005) 187-197
36. Rosen C.L., D'Andrea L., and Haddad G.G. Adult criteria for obstructive sleep apnea do not identify children with serious obstruction. Am. Rev. Respir. Dis. 146 (1992) 1231-1234
37. N.W. Barton, R.O. Brady, J.M. Dambrosia, A.M. Di Bisceglie, S.H. Doppelt, S.C. Hill, H.J. Mankin, G.J. Murray, R.I. Parker, C.E. Argoff, and Collaborators, Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease, N. Engl. J. Med. 324 (1991) 1464-1470.
38. Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., and Zimran A. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113 (2002) 112-119
39. Schiffmann R., Floeter M.K., Dambrosia J.M., Gupta S., Moore D.F., Sharabi Y., Khurana R.K., and Brady R.O. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 28 (2003) 703-710
40. Redelmeier D.A., Bayoumi A.M., Goldstein R.S., and Guyatt G.H. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am. J. Respir. Crit. Care Med. 155 (1997) 1278-1282